Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Society for Laboratory Automation and Screening Adopts Strategic Plan

By LabMedica International staff writers
Posted on 25 Oct 2010
The newly formed Society for Laboratory Automation and Screening (SLAS) has revealed its inaugural strategic plan, which will be used to establish a framework within which the society will objectively assess, justify, and build programs, products, services, and events.

According to SLAS CEO Greg Dummer, "this plan thoughtfully outlines where our organization expects to go over the next few years, how it's going to get there, and how we'll know if it got there or not. More...
It is a decision-making tool that defines our direction and provides a context for assessing tangible action plans and appropriately allocating resources.”

The SLAS mission is to be the preeminent global organization providing forums for education and information exchange, and to encourage the study of and improve the science and practice of laboratory automation and screening.

The strategic plan is organized into four primary focus areas: defining and expanding the scope of SLAS; connecting the global community to SLAS content; cultivating partnerships for enhanced member opportunities; and developing a world-class organization.

The goal of the society is to be a multidisciplinary organization serving academia, industry, government organizations, private institutes, and technology providers across geographic borders.

The Society for Laboratory Automation and Screening (SLAS) is a new nonprofit scientific organization uniting the former Society for Biomolecular Sciences (SBS) and the Association for Laboratory Automation (ALA).

The SLAS Strategic Plan is presented in its entirety at the society's new website.

Related Links:

Society for Laboratory Automation and Screening






Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.